Physician
Oncology
Dr. Joyce A. O'Shaughnessy, MD
|
|
Give Review
Joyce A. O'Shaughnessy, MD practices Oncology. She researched medicine at Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care She has 4 awards "America's Top Doctors", "America's Top Doctors for Cancer", "Meaningful Use Stage 1 Certification" and "Super Doctor". Dr. Joyce A. O'Shaughnessy is also published. She has 63 publications published. The lastest publication: "Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.'
Publications
- Identification of early breast Cancer patient cohorts who may benefit from lapatinib therapy.
- Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Ca...
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast Cancer previously treated with an anthracycline, a taxane, and capec...
- Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast Cancer: a randomized placebo-controlled phase...
- Abiraterone acetate, exemestane or the combination in post-menopausal patients with estrogen receptor-positive metastatic breast Cancer.
- Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HE...
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer.
- Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast Cancer.
- Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer.
- BRAF V600E-mutated lung adenoCarcinoma with metastases to the brain responding to treatment with vemurafenib.
- Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast Cancer.
- General discussion.
- Improving quality of life in patients with metastatic breast Cancer.
- Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast Cancer: Results of an exploratory ana...
- Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast Cancer patients.
- Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast Cancer: a single-group, open-label, phase 2 study.
- nab-Paclitaxel for first-line treatment of patients with metastatic breast Cancer and poor prognostic factors: a retrospective analysis.
- Genome and transcriptome sequencing in prospective metastatic triple-negative breast Cancer uncovers therapeutic vulnerabilities.
- Adjuvant lapatinib for women with early-stage HER2-positive breast Cancer: a randomised, controlled, phase 3 trial.
- Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer.
- Tamoxifen Downregulates Ets-oncogene Family Members ETV4 and ETV5 in Benign Breast Tissue: Implications for Durable Risk Reduction.
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast Cancer after prior H...
- A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast Cancer who have received prior taxane therapy.
- Lethal breast Cancer.
- Docetaxel With Cyclophosphamide Is Associated With an OVerall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research...
- RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast Cancer.
- Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast Cancer.
- Novel taxane formulations in the treatment of breast Cancer: a thought leader discussion and consensus roundtable.
- Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast Cancer heavily pretreated with taxanes.
- Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast Cancer.
- Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast Cancer.
- Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast Cancer previously treated with every-3-week taxane therapy.
- Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast Cancer.
- Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast Cancer.
- Molecular signatures predict outcomes of breast Cancer.
- Capecitabine/Taxane combination therapy: evolving clinical utility in breast Cancer.
- Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast Cancer.
- Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast Cancer.
- Pegfilgrastim: recent advances in the prophylaxis of chemotherapy-induced Neutropenia.
- Highlights from: Third Annual Future of Supportive Therapy in Oncology, San Francisco, CA; 27th Annual, San Antonio Breast Cancer Symposium, San Antonio, TX; 46th Annu...
- Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast Cancer undergoing adjuvant or neoadjuvant chemotherapy.
- Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.
- Breast Cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
- Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast Cancer.
- Current comprehensive assessment and management of women at increased risk for breast Cancer.
- New perspectives with antimetabolites in the management of breast Cancer.
- Pegylated liposomal doxorubicin in the treatment of breast Cancer.
- Chemotherapy-induced cognitive dysfunction: a clearer picture.
- Erythropoietin as a critical component of breast Cancer therapy: survival, synergistic, and cognitive applications.
- Ductal lavage: clinical utility and future promise.
- Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of Cancer chemopreventive agent...
- The evolving role of capecitabine in breast Cancer.
- Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast Cancer.
- Pemetrexed: an active new agent for breast Cancer.
- Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast Cancer undergoing adjuvant chemotherapy.
- Management of premenopausal women with early-stage breast Cancer: is there a role for ovarian suppression?
- Evaluation and management of the woman with an abnormal ductal lavage.
- Pemetrexed: a promising new treatment for breast Cancer.
- Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
- Ductal lavage and the clinical management of women at high risk for Breast carcinoma: a commentary.
- Eribulin monotherapy in patients aged 70 years and older with metastatic breast Cancer.
- The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic b...
Schools
Yale Univ Sch Of Med
Massachusetts General Hospital
National Cancer Institute
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Massachusetts General Hospital -
Yale University School of Medicine
Hospital
-
Baylor University Medical Center -
Medical City Dallas Hospital
Drug Facts
| NPI NUMBER | 1790727709 | |
| NPPES Provider LastName | O'SHAUGHNESSY | |
| NPPES Provider FirstName | JOYCE | |
| NPPES Provider ZIPCode | 752462003 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1297.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 23.0 | |
| Percent Opioid Claims | 1.77 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1790727709 |
| Last Name Of The Provider | O'SHAUGHNESSY |
| First Name Of The Provider | JOYCE |
| View All |
Similar Doctors
|
|
Dr. Robert G. Mennel, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric S. Nadler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kartik Konduri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cheryl A. Harth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Micah M. Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin D. Courtney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minal A. Barve, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John D. Minna, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Carlos H. Becerra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ashwani K. Agarwal, MB
This Doctor is OpenDoctor Recommended.
|